Should Evidence-Based Proof of Drug Efficacy be Extrapolated to a "Class of Agents"?

Circulation

Volumn 108, Issue 21, 2003, Pages 2608-2610

  Furberg, Curt D ^a   Psaty, Bruce M ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; CAPTOPRIL; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENCAINIDE; FOSINOPRIL; LISINOPRIL; MIBEFRADIL; MOEXIPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; TROGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PHARMACEUTICAL PREPARATIONS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0345014786     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000090572.51900.92     Document Type: Short Survey

References (10)

1. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol. 2001;37:1456-1460.
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
3. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
4. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001;87:1058-1063.
5. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.
6. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet. 1999;354:1202-1204.
7. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
8. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensinconverting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol. 1998;82:465-469.
9. National Institute for Health Care Management, Research and Educational Foundation. Prescription Drug Expenditures in 2001: Another Year of Escalating Costs. Revised May 6, 2002. Available at: http:// www.nihcm.org/spending2001.pdf. Accessed October 6, 2003.
10. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.